• Like
Bioinformatics partnering terms and agreements
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Bioinformatics partnering terms and agreements

  • 56 views
Published

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
56
On SlideShare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
1
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Bioinformatics Partnering Terms and Agreements The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding andunprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leadinghealthcare companies. Trends in bioinformatics partnering deals Deal terms analysis Partnering agreement structure Partneringcontract documents Top deals by value Most active dealmakers Average deal terms for bioinformatics TheBioinformatics Partnering Terms and Agreements report provides comprehensive understanding andunprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leadinghealthcare companies.The report provides a detailed understanding and analysis of how and why companies enter bioinformaticspartnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an optionright to license the licensors bioinformatics technology. These deals tend to be multicomponent, starting withcollaborative R&D, and commercialization of outcomes.This report provides details of the latest bioinformatics agreements announced in the healthcare sectors.Bioinformatics is the application of computer science and information technology to the field of biology andmedicine. Bioinformatics deals with algorithms, databases, information systems, web technologies, artificialintelligence, information and computation theory, software engineering, data mining, image processing,modeling, simulation, signal processing, discrete mathematics, control systems, and statistics, for generatingnew knowledge of biology and medicine. Bioinformatics deals have increased in terms of popularity for partnering in the past decade, as computingpower has been embraced in order to speed up the discovery, evaluation and clinical assessment processes.Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insightinto the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilstmany smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms ofhow payments are triggered – contract documents provide this insight where press releases anddatabases do not.This report contains a comprehensive listing of all bioinformatics partnering deals announced since January2007, including financial terms where available, including over 1500 links to online deal records of actualbioinformatics partnering deals as disclosed by the deal parties. In addition, where available, records includecontract documents as submitted to the Securities Exchange Commission by companies and their partners.The initial chapters of this report provide an orientation of bioinformatics dealmaking and business activities.Bioinformatics Partnering Terms and Agreements
  • 2. Chapter 1 provides an introduction to the report, whilst Chapter 2 provides an overview of the trends in bioinformatics dealmaking since 2007, including details ofaverage headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading bioinformatics deals since 2007. Deals are listed by headlinevalue, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where thedeal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summaryfollowed by a comprehensive listing of bioinformatics deals, as well as contract documents available in thepublic domain. Where available, each deal title links via Weblink to an online version of the actual contractdocument, providing easy access to each contract document on demand.Chapter 5 provides a comprehensive and detailed review of bioinformatics partnering deals signed andannounced since January 2007, where a contract document is available in the public domain. The chapter isorganized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), andspecific therapy focus. Each deal title links via Weblink to an online version of the deal record and whereavailable, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided organized by bioinformatics partnering company A-Z ,deal type definitions and bioinformatics partnering agreements example. Each deal title links via Weblink toan online version of the deal record and where available, the contract document, providing easy access to eachcontract document on demand.The report also includes numerous tables and figures that illustrate the trends and activities in bioinformaticspartnering and dealmaking since 2007.In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in theresearch, development and commercialization of bioinformatics technologies and products.Bioinformatics Partnering Terms and Agreements provides the reader with the following key benefits: In-depth understanding of bioinformatics deal trends since 2007 Access to headline, upfront, milestone androyalty data Analysis of the structure of bioinformatics agreements with numerous real life case studiesComprehensive access to over 1500 actual vaccine contracts entered into by the world’s biopharmacompanies Detailed access to actual bioinformatics contracts enter into by the leading fifty bigpharmacompanies Insight into the terms included in a bioinformatics agreement, together with real world clauseexamples Understand the key deal terms companies have agreed in previous deals Undertake due diligence toassess suitability of your proposed deal terms for partner companies Report scope Bioinformatics Partnering Terms and Agreements is intended to provide the reader with an in-depthunderstanding and access to bioinformatics trends and structure of deals entered into by leading companiesworldwide.Bioinformatics Partnering Terms and Agreements
  • 3. Bioinformatics Partnering Terms and Agreements includes: Trends in bioinformatics dealmaking in the biopharma industry since 2007 o Analysis of bioinformatics dealstructure Access to headline, upfront, milestone and royalty data o Case studies of real-life bioinformaticsdeals o Access to over 1500 bioinformatics contract documents The leading bioinformatics deals by valuesince 2005 o Most active bioinformatics dealmakers since 2007 The leading bioinformatics partneringresources In Bioinformatics Partnering Terms and Agreements, the available contracts are listed by: oCompany A-Z o Headline value Stage of development at signing o Deal component type Specific therapytarget Each deal title links via Weblink to an online version of the deal record and where available, thecontract document, providing easy access to each contract document on demand. The BioinformaticsPartnering Terms and Agreements report provides comprehensive access to available deals and contractdocuments for over 1,500 bioinformatics deals. Analyzing actual contract agreements allows assessment of thefollowing: What are the precise bioinformatics rights granted or optioned? What is actually granted by the agreement tothe partner company? What exclusivity is granted? What is the payment structure for the deal? o How aresales and payments audited? What is the deal term? How are the key terms of the agreement defined? How areIPRs handled and owned? o Who is responsible for commercialization? Who is responsible for development,supply, and manufacture? How is confidentiality and publication managed? o How are disputes to beresolved? Under what conditions can the deal be terminated? o What happens when there is a change ofownership? What sublicensing and subcontracting provisions have been agreed? o Which boilerplate clausesdoes the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal typeto deal type? Which jurisdiction does the company insist upon for agreement law?table Of Contentexecutive Summarychapter 1 – Introductionchapter 2 – Trends In Bioinformatics Dealmaking2.1. Introduction2.2. Bioinformatics Partnering Over The Years2.3. Bigpharma Bioinformatics Dealmaking Activity2.4. Bigpharma Not Active In Bioinformatics Partnering2.5. Bioinformatics Partnering By Deal Type2.6. Bioinformatics Partnering By Stage Of Development2.7. Bioinformatics Partnering By Disease Type2.8. Average Deal Terms For Bioinformatics Partnering2.8.1 Bioinformatics Partnering Headline Values2.8.2 Bioinformatics Deal Upfront PaymentsBioinformatics Partnering Terms and Agreements
  • 4. 2.8.3 Bioinformatics Deal Milestone Payments2.8.4 Bioinformatics Royalty Rateschapter 3 – Leading Bioinformatics Deals3.1. Introduction3.2. Top Bioinformatics Deals By Value3.3. Top Bioinformatics Deals Involving Bigpharmachapter 4 – Bigpharma Bioinformatics Deals4.1. Introduction4.2. How To Use Bigpharma Bioinformatics Partnering Deals4.3. Bigpharma Bioinformatics Partnering Company Profilesabbottallerganamgenastellasastrazenecabaxter Internationalbayerbiogen Idecboehringer Ingelheimbristol-myers Squibbdaiichi Sankyoeisaieli Lillygaldermaglaxosmithklinegrifolshospira 73johnson & Johnsonmerck & Comerck Kgaamitsubishi Tanabenovartisnovo NordiskotsukapfizerpurduerochesanofiserviershireBioinformatics Partnering Terms and Agreements
  • 5. takedatevaucbvaleantchapter 5 – Bioinformatics Dealmaking Directory5.1. Introduction5.2. By Stage Of Developmentdiscoveryformulationmarketedphase Iphase Iiphase Iiipreclinicalregulatory5.3. By Deal Typeasset Purchasebigpharma Outlicensingco-developmentcollaborative R&dco-marketcontract Serviceco-promotioncradacross-licensingdevelopmentdistributionequity Purchaseevaluationgrantinterestsjoint Venturelicensinglitigationloanmanufacturingmanufacturing - OemmarketingoptionpromotionresearchBioinformatics Partnering Terms and Agreements
  • 6. settlementspin Outsub-licensesupplytechnology Transfertermination5.4. By Therapy Areaanaestheticsbreastcardiovascularcentral Nervous Systemdentaldermatologygastrointestinalgenetic Disordersgenitourinarygynaecologyhematologyhospital Careimmunologyinfectivesmetabolicmusculoskeletalobstetricsoncologyophthalmicspediatricspsychiatrypublic Healthrespiratorysensory Organssexual Healthchapter 6 – Partnering Resource Center 6.1. Online Partnering 6.2. Partnering Events 6.3. Further Reading On Dealmaking about Wildwood Ventures current Partnering current Agreements current Reports recent Report Titles From Current Partnering order Form – ReportsBioinformatics Partnering Terms and Agreements
  • 7. About Us:Transparency Market Research is a market intelligence company providing global business informationreports and services. Our exclusive blend of quantitative forecasting and trends analysis providesforward-looking insight for thousands of decision makers. We are privileged with highly experienced team ofAnalysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques togather, and analyze information. Our business offerings represent the latest and the most reliable informationindispensable for businesses to sustain a competitive edge.Contact:ResearchMoz90 State Street,Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usBlog: http://researchmoz.blogspot.com/Website: http://www.researchmoz.us/Bioinformatics Partnering Terms and Agreements